[go: up one dir, main page]

MX2017013797A - Inhibidor de janus quinasa. - Google Patents

Inhibidor de janus quinasa.

Info

Publication number
MX2017013797A
MX2017013797A MX2017013797A MX2017013797A MX2017013797A MX 2017013797 A MX2017013797 A MX 2017013797A MX 2017013797 A MX2017013797 A MX 2017013797A MX 2017013797 A MX2017013797 A MX 2017013797A MX 2017013797 A MX2017013797 A MX 2017013797A
Authority
MX
Mexico
Prior art keywords
janus kinase
kinase inhibitor
formula
jak
drugs
Prior art date
Application number
MX2017013797A
Other languages
English (en)
Other versions
MX381994B (es
Inventor
Hao Wu
Chen Shuhui
Mao Weiwei
Fan Lili
Huang Yiqiang
Original Assignee
Wuxi Fortune Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Fortune Pharmaceutical Co Ltd filed Critical Wuxi Fortune Pharmaceutical Co Ltd
Publication of MX2017013797A publication Critical patent/MX2017013797A/es
Publication of MX381994B publication Critical patent/MX381994B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen una serie de inhibidores de Janus quinasa, y particularmente se describe un compuesto o sales farmacéuticamente aceptables del mismo de Fórmula (I) y su uso en la preparación de fármacos para tratar enfermedades relacionadas con Janus quinasa (JAK). (ver Fórmula).
MX2017013797A 2015-05-29 2016-05-26 Inhibidor de janus quinasa. MX381994B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510289933 2015-05-29
CN201610344370 2016-05-23
PCT/CN2016/083426 WO2016192563A1 (zh) 2015-05-29 2016-05-26 Janus激酶抑制剂

Publications (2)

Publication Number Publication Date
MX2017013797A true MX2017013797A (es) 2018-03-21
MX381994B MX381994B (es) 2025-03-13

Family

ID=57440054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013797A MX381994B (es) 2015-05-29 2016-05-26 Inhibidor de janus quinasa.

Country Status (17)

Country Link
US (1) US10174056B2 (es)
EP (1) EP3305788B1 (es)
JP (1) JP6564473B2 (es)
KR (1) KR102081272B1 (es)
CN (1) CN107531711B (es)
AU (1) AU2016271904B2 (es)
CA (1) CA2983481C (es)
DK (1) DK3305788T3 (es)
EA (1) EA036063B1 (es)
ES (1) ES2822748T3 (es)
HU (1) HUE050842T2 (es)
MX (1) MX381994B (es)
PL (1) PL3305788T3 (es)
PT (1) PT3305788T (es)
TW (1) TWI692481B (es)
UA (1) UA118822C2 (es)
WO (1) WO2016192563A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033456C (en) * 2016-11-23 2021-03-09 Wuxi Fortune Pharmaceutical Co., Ltd Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof
WO2019061299A1 (en) * 2017-09-29 2019-04-04 Rhodia Operations PROCESS FOR THE PREPARATION OF AMINOMETHYL-SUBSTITUTED HETEROCYCLOCCANE
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107778321A (zh) * 2017-10-31 2018-03-09 无锡福祈制药有限公司 一种托法替尼类似物
CN107602591A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物
CN107573364A (zh) * 2017-10-31 2018-01-12 无锡福祈制药有限公司 一种jak激酶抑制剂
CN107602590A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 具有Janus激酶抑制活性的桥环化合物
KR102857917B1 (ko) 2019-01-30 2025-09-10 펠리카메드 바이오테크놀로지 컴퍼니 리미티드 Jak 억제제 및 그 제조 방법
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CN113939514B (zh) * 2019-06-05 2022-12-27 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物及其应用
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN111004236B (zh) * 2019-12-19 2022-04-05 卓和药业集团股份有限公司 一种wxfl10203614中间体的动态动力学拆分方法
CN110923288A (zh) * 2019-12-19 2020-03-27 卓和药业集团有限公司 一种wxfl10203614中间体的生物学拆分方法
CN111087412B (zh) * 2019-12-31 2021-04-09 卓和药业集团有限公司 一类吡咯并嘧啶衍生物及其合成方法
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112168827A (zh) * 2020-11-03 2021-01-05 卓和药业集团有限公司 一种用于治疗银屑病的药物组合物及其制备方法
CN113372343B (zh) * 2020-12-04 2022-07-29 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000885B1 (hr) * 1998-06-19 2007-03-31 Pfizer Products Inc. PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
AP1893A (en) 2000-12-01 2008-09-23 Osi Pharm Inc Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
CA2759026C (en) * 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CN102985424B (zh) 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
WO2013088256A1 (en) * 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors
EP2796460B1 (en) * 2011-12-21 2018-07-04 Jiangsu Hengrui Medicine Co. Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
US8551542B1 (en) 2012-09-20 2013-10-08 Basic Research L.L.C. Methods and compositions for increasing growth hormones
CN105008362B (zh) * 2013-02-22 2017-06-06 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
ES2654051T3 (es) * 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
SI2994454T1 (sl) 2013-12-09 2019-05-31 Unichem Laboratories Limited Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metil piperidin-3-il)-metil amina
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Also Published As

Publication number Publication date
CN107531711A (zh) 2018-01-02
TW201706277A (zh) 2017-02-16
MX381994B (es) 2025-03-13
UA118822C2 (uk) 2019-03-11
KR20170141787A (ko) 2017-12-26
JP6564473B2 (ja) 2019-08-21
US20180162879A1 (en) 2018-06-14
DK3305788T3 (da) 2020-09-28
ES2822748T3 (es) 2021-05-04
JP2018516264A (ja) 2018-06-21
CN107531711B (zh) 2020-03-31
KR102081272B1 (ko) 2020-02-25
EP3305788B1 (en) 2020-08-05
PT3305788T (pt) 2020-09-25
US10174056B2 (en) 2019-01-08
EA036063B1 (ru) 2020-09-22
HUE050842T2 (hu) 2021-01-28
CA2983481A1 (en) 2016-12-08
EP3305788A4 (en) 2018-11-07
AU2016271904A1 (en) 2017-11-09
PL3305788T3 (pl) 2021-03-08
CA2983481C (en) 2020-04-14
EP3305788A1 (en) 2018-04-11
EA201792116A1 (ru) 2018-07-31
WO2016192563A1 (zh) 2016-12-08
TWI692481B (zh) 2020-05-01
AU2016271904B2 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2017013797A (es) Inhibidor de janus quinasa.
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
MX2017009449A (es) Inhibidor jak.
JOP20220008A1 (ar) مثبطات parp1
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CO2017011996A2 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112017023225A2 (pt) inibidor de proteína cinase
MX2019006843A (es) Inhibidor de cdk4/6.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
BR112017008867A2 (pt) inibidores de proteína quinases
AR100289A1 (es) Formas de un inhibidor de pi3k